Clinical Analysis Of Recombinant Human Granulocyte Colony Stimulating Factor In The Treatment Of Breast Cancer After Chemotherapy

International guidelines for the American society of clinical oncology(ASCO),the European organization for research and treatment of cancer(EORTC)and the national comprehensive cancer network(NCCN),joint recommendation when 20% or greater incidence of FN,give patients the prophylactic use of rhG CSF,however,in the actual clinical application of supplementary guidelines is divided,because there are so many clinical chemotherapy regimens and clinical situation,and their FN risk assessment in the literature is not clear,so they cannot be for scientific FN risk assessment.So for personal overall FN clinical risk factors according to still need further study.In European countries on patients with early breast cancer and lymphoma research has shown that follows the international guidelines for the use of rhG CSF-very few,almost half of the patients in the chemotherapy delays and reduced doses of chemotherapy,and in our country for preventive application of rhG CSF-also has the same problem,so we need to further study the use of rhG CSF-for better understanding.Objective1.To observe the effect of rhG-CSF on bone marrow depression after chemotherapy in breast cancer patients.2.To observe the effect of different doses of rhG-CSF.3.To observe the necessity of using rhG-CSF the treatment of different chemotherapy cycles.MethodRetrospec-tive survey method,Screening for Breast Cancer at least three cycles of TEC regimen and 24-48 h after chemotherapy with rhG CSF150 ug or 300ug5 days as treatment group,rhG CSF was not given as the control group.In reducing blood and febrile neutropenia were observed before and after the first chemotherapy cycle and three cycles of chemotherapy(febrileneutropenia,FN)incidence rate,And carries on the statistical analysis to the index.ResultThe total number of white blood cells and neutrophils in the treatment group(1,2,4,5)after chemotherapy were higher than those in the control group(3,6),the incidence of FN was lower than that of the control group,and the difference was statistically significant(P<0.05).There was no significant difference in the incidence of thrombocytopenia in the treatment group and the control group(P>0.05).There was no significant difference in the effects of different doses of rhG-CSF(P>0.05)on the reduction of WBC,granulocyte and FN in the same chemotherapy cycle.In the first chemotherapy cycle control group(3),the incidence of FN was significantly lower than that of the third cycle control group(6),the difference was statistically significant(P<0.05).Conclusion1 RhG-CSF in the prevention of bone marrow suppression after breast cancer surgery and chemotherapy induced by the combination of paclitaxel and the treatment of the patients with good curative effect.2 RhG-CSF is recommended for low dose prevention.3 To prevent the use of rhG-CSF after chemotherapy in patients with multiple chemotherapy.